<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000601318"><TermName>bendamustine</TermName><TermPronunciation>(BEN-duh-MUS-teen)</TermPronunciation><TermDefinition><DefinitionText>The active ingredient in a drug that is used to treat chronic lymphocytic leukemia (CLL), to treat slow-growing B-cell non-Hodgkin lymphoma (NHL) that has gotten worse within 6 months of treatment with other anticancer drugs, and is being studied in the treatment of other types of cancer. Bendamustine may damage the DNA in cancer cells and cause them to die. It is a type of alkylating agent and a type of antimetabolite. </DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000720998" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;bendamustine&quot;" language="en" id="_3"/><MediaLink ref="CDR0000720999" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;bendamustina&quot;" language="es" id="_4"/><SpanishTermName>bendamustina</SpanishTermName><SpanishTermDefinition><DefinitionText>Ingrediente activo de un medicamento que se usa para tratar la leucemia linfocítica crónica (LLC), para tratar el linfoma no Hodgkin (LNH) de células B de crecimiento lento que empeoró dentro de los seis meses de tratamiento con otros medicamentos contra el cáncer y que está en estudio para el tratamiento de otros tipos de cáncer. La bendamustina puede dañar el ADN de las células cancerosas y destruirlas. Es un tipo de alquilante y un tipo de antimetabolito.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2008-07-18</DateFirstPublished><DateLastModified>2010-03-29</DateLastModified><RelatedInformation><RelatedDrugSummaryRef href="CDR0000592692">Bendamustine Hydrochloride</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
